W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Decision
P/0094/2022 : EMA decision of 11 March 2022 on the granting of a product specific waiver for human normal immunoglobulin (Flebogamma 5% DIF) (EMEA-003121-PIP01-21)